Frontiers in Public Health (May 2023)

Recombinant mycobacterium tuberculosis fusion protein for diagnosis of mycobacterium tuberculosis infection: a short-term economic evaluation

  • Zheng Liu,
  • Zheng Liu,
  • Zheng Liu,
  • Zheng Liu,
  • Zheng Liu,
  • Sha Diao,
  • Sha Diao,
  • Sha Diao,
  • Sha Diao,
  • Linan Zeng,
  • Linan Zeng,
  • Linan Zeng,
  • Linan Zeng,
  • Dan Liu,
  • Dan Liu,
  • Dan Liu,
  • Dan Liu,
  • Dan Liu,
  • Xuefeng Jiao,
  • Xuefeng Jiao,
  • Xuefeng Jiao,
  • Xuefeng Jiao,
  • Zhe Chen,
  • Zhe Chen,
  • Zhe Chen,
  • Zhe Chen,
  • Zhe Chen,
  • Xiao Cheng,
  • Xiao Cheng,
  • Xiao Cheng,
  • Xiao Cheng,
  • Xiaofeng Ni,
  • Xiaofeng Ni,
  • Xiaofeng Ni,
  • Xiaofeng Ni,
  • Siyi He,
  • Siyi He,
  • Siyi He,
  • Siyi He,
  • Siyi He,
  • Bin Wu,
  • Deying Kang,
  • Chaomin Wan,
  • Chaomin Wan,
  • Rongsheng Zhao,
  • Huiqing Wang,
  • Lingli Zhang,
  • Lingli Zhang,
  • Lingli Zhang,
  • Lingli Zhang,
  • Lingli Zhang

DOI
https://doi.org/10.3389/fpubh.2023.1105857
Journal volume & issue
Vol. 11

Abstract

Read online

ObjectivesRecombinant Mycobacterium tuberculosis fusion protein (EC) was anticipated to be used for the scale-up of clinical application for diagnosis of Mycobacterium tuberculosis infection in China, but it lacked a head-to-head economic evaluation based on the Chinese population. This study aimed to estimate the cost-utility and the cost-effectiveness of both EC and tuberculin pure protein derivative (TB-PPD) for diagnosis of Mycobacterium tuberculosis infection in the short term.MethodsFrom a Chinese societal perspective, both cost-utility analysis and cost-effectiveness analysis were performed to evaluate the economics of EC and TB-PPD for a one-year period based on clinical trials and decision tree model, with quality-adjusted life years (QALYs) as the utility-measured primary outcome and diagnostic performance (including the misdiagnosis rate, the omission diagnostic rate, the number of patients correctly classified, and the number of tuberculosis cases avoided) as the effective-measured secondary outcome. One-way and probabilistic sensitivity analyses were performed to validate the robustness of the base-case analysis, and a scenario analysis was conducted to evaluate the difference in the charging method between EC and TB-PPD.ResultsThe base-case analysis showed that, compared with TB-PPD, EC was the dominant strategy with an incremental cost-utility ratio (ICUR) of saving 192,043.60 CNY per QALY gained, and with an incremental cost-effectiveness ratio (ICER) of saving 7,263.53 CNY per misdiagnosis rate reduction. In addition, there was no statistical difference in terms of the omission diagnostic rate, the number of patients correctly classified, and the number of tuberculosis cases avoided, and EC was a similar cost-saving strategy with a lower test cost (98.00 CNY) than that of TB-PPD (136.78 CNY). The sensitivity analysis showed the robustness of cost-utility and cost-effectiveness analysis, and the scenario analysis indicated cost-utility in EC and cost-effectiveness in TB-PPD.ConclusionThis economic evaluation from a societal perspective showed that, compared to TB-PPD, EC was likely to be a cost-utility and cost-effective intervention in the short term in China.

Keywords